Symptoms & Symptom Management
High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer
ERJ Open Research 2021 March 22 [Link] Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath Abstract Background: Programmed cell death protein 1 (PD-1)/programmed cell death protein ligand 1 (PD-L1) immune checkpoint inhibitors have been approved for monotherapy…
Read MoreUse of preclinical models for malignant pleural mesothelioma
Thorax 2021 March 10 [Link] Marie Shamseddin, Joanna Obacz, Mathew J Garnett, Robert Campbell Rintoul, Hayley Elizabeth Francies, Stefan John Marciniak Abstract Malignant pleural mesothelioma (MPM) is an aggressive cancer most commonly caused by prior exposure to asbestos. Median survival is 12-18 months, since surgery is ineffective and chemotherapy offers minimal benefit. Preclinical models that…
Read MoreSyndecan-1 Overexpressing Mesothelioma Cells Inhibit Proliferation, Wound Healing, and Tube Formation of Endothelial Cells
Cancers 2021 February 6 [Link] Joman Javadi, Ghazal Heidari-Hamedani, Angelika Schmalzl, Tünde Szatmári, Muzaffer Metintas, Pontus Aspenström, Anders Hjerpe, Katalin Dobra Abstract Malignant mesothelioma (MM) is an aggressive tumor of the serosal cavities. Angiogenesis is important for mesothelioma progression, but so far, anti-angiogenic agents have not improved patient survival. Our hypothesis is that better understanding…
Read MoreHigher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma
Cancer Cytopathology 2021 January 25 [Link] Mohammed S I Mansour, Tomas Seidal, Ulrich Mager, Katalin Dobra, Hans Brunnström, Annika Dejmek Abstract Background: Malignant mesothelioma (MM) is a therapy-resistant tumor, often causing an effusion. Drugs targeting the programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have shown promising results, but assessment of PD-L1…
Read MoreFluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma
Cancer Cytopathology 2021 January 25 [Link] Yoshiaki Kinoshita, Makoto Hamasaki, Shinji Matsumoto, Masayo Yoshimura, Ayuko Sato, Tohru Tsujimura, Toshiaki Kamei, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima Abstract Background: Malignant pleural mesothelioma (MPM) is characterized by mutations in several genes, including cyclin-dependent kinase-inhibitor 2A/p16 in the 9p21 locus, BRCA1-associated protein 1 (BAP1), and neurofibromatosis type 2…
Read MoreCost-Effectiveness of Malignant Pleural Effusion with Indwelling Catheter: Systematic Review
Journal of Palliative Medicine 2020 December 30 [Link] Maribel Botana-Rial, Cristina Ramos-Hernández, Irene Lojo-Rodríguez, Cristina Represas-Represas, Alberto Ruano-Raviña, Virginia Leiro-Fernández, Alberto Fernández-Villar Abstract Background: The current cost of treatment of malignant pleural effusion (MPE) with an indwelling pleural catheter (IPC) is unclear. Objective: We propose a review of the scientific evidence on the cost and…
Read MoreMalignant pleural neoplasm with both differentiation of epithelioid mesothelioma and squamous-cell carcinoma, a rare phenomena
Diagnostic Cytopathology 2020 December 21 [Link] Ashley Re, David Shersher, Ashleigh Allen, Roland Schwarting, Shuyue Ren Abstract Malignant mesothelioma, a neoplasm arising within the serosal surfaces, has been linked closely to asbestos exposure. We present a case of 72-year-old male with a 27 year work-related history of asbestos exposure who presented with dyspnea. Chest computed…
Read MoreComplications and Predictive Factors for Air Leak > 10 Days with Neoadjuvant Chemotherapy Followed by Pleurectomy/Decortication for Malignant Pleural Mesothelioma
Annals of Surgical Oncology 2020 October [Link] Akifumi Nakamura, Nobuyuki Kondo, Toru Nakamichi, Masaki Hashimoto, Teruhisa Takuwa, Seiji Matsumoto, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa Abstract Background: A few studies have reported the incidence and clinical implications of complications after pleurectomy/decortication (P/D). Objective: The aim of this study was to assess the details of complications…
Read MoreThe phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology 2020 October 6 [Link] Ben Davidson, Annika Jøntvedt Bock, Arild Holth, Dag Andre Nymoen Abstract Objective: To analyze the expression and clinical role of the phosphatase PTPN1 (PTP1B) in serous effusions. Methods: PTPN1 mRNA expression by quantitative RT-PCR was analyzed in 83 high-grade serous carcinoma (HGSC) and 15 malignant mesothelioma (MM) effusions. PTP1B and…
Read MoreUsing creative co-design to develop a decision support tool for people with malignant pleural effusion
BMC Medical Informatics and Decision Making 2020 August 5 [Link] Cheryl Grindell, Angela Tod, Remi Bec, Daniel Wolstenholme, Rahul Bhatnagar, Parthipan Sivakumar, Anna Morley, Jayne Holme, Judith Lyons, Maryam Ahmed, Susan Jackson, Deirdre Wallace, Farinaz Noorzad, Meera Kamalanathan, Liju Ahmed, Mathew Evison Abstract Background: Malignant pleural effusion (MPE) is a common, serious problem predominantly seen…
Read More